Underutilisation of breast cancer prevention medication in Australia

Underutilisation of breast cancer prevention medication in Australia

Increased implementation of proven prevention strategies is required to combat rising breast cancer incidence. We assessed use of risk reducing medication (RRMed) by Australian women at elevated breast cancer risk. Only 2.4% had ever used RRMed. Higher breast cancer risk was statistically significan...

Full description

Bibliographic Details
Main Authors: Courtney Macdonald, James A. Chamberlain, Danielle Mazza, Roger L. Milne, Kelly-Anne Phillips
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Breast
Subjects:
Breast cancer
Prevention
Chemoprevention
Tamoxifen
Risk
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621004434
id doaj-018fca9a65ea4b488e305e50a6c51cfa
record_format Article
spelling doaj-018fca9a65ea4b488e305e50a6c51cfa2021-08-28T04:41:37ZengElsevierBreast1532-30802021-12-01603537Underutilisation of breast cancer prevention medication in AustraliaCourtney Macdonald0James A. Chamberlain1Danielle Mazza2Roger L. Milne3Kelly-Anne Phillips4Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AustraliaCancer Epidemiology Division, Cancer Council Victoria, Melbourne, AustraliaDepartment of General Practice, Monash University, Melbourne, AustraliaCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Melbourne, AustraliaDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia; Corresponding author. Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria, 8006, Australia.Increased implementation of proven prevention strategies is required to combat rising breast cancer incidence. We assessed use of risk reducing medication (RRMed) by Australian women at elevated breast cancer risk. Only 2.4% had ever used RRMed. Higher breast cancer risk was statistically significantly associated with use of RRMed (OR 1.82, 95%CI: 1.08–3.07, p = 0.02 for ≥30% lifetime risk compared with 16%–29% lifetime risk), but parity, education level and family history of breast cancer were not. Breast cancer prevention medications are underutilised. Efforts are needed to incorporate breast cancer risk assessment and risk management discussions into routine health assessments for women.http://www.sciencedirect.com/science/article/pii/S0960977621004434Breast cancerPreventionChemopreventionTamoxifenRisk
collection DOAJ
language English
format Article
sources DOAJ
author Courtney Macdonald
James A. Chamberlain
Danielle Mazza
Roger L. Milne
Kelly-Anne Phillips
spellingShingle Courtney Macdonald
James A. Chamberlain
Danielle Mazza
Roger L. Milne
Kelly-Anne Phillips
Underutilisation of breast cancer prevention medication in Australia
Breast
Breast cancer
Prevention
Chemoprevention
Tamoxifen
Risk
author_facet Courtney Macdonald
James A. Chamberlain
Danielle Mazza
Roger L. Milne
Kelly-Anne Phillips
author_sort Courtney Macdonald
title Underutilisation of breast cancer prevention medication in Australia
title_short Underutilisation of breast cancer prevention medication in Australia
title_full Underutilisation of breast cancer prevention medication in Australia
title_fullStr Underutilisation of breast cancer prevention medication in Australia
title_full_unstemmed Underutilisation of breast cancer prevention medication in Australia
title_sort underutilisation of breast cancer prevention medication in australia
publisher Elsevier
series Breast
issn 1532-3080
publishDate 2021-12-01
description Increased implementation of proven prevention strategies is required to combat rising breast cancer incidence. We assessed use of risk reducing medication (RRMed) by Australian women at elevated breast cancer risk. Only 2.4% had ever used RRMed. Higher breast cancer risk was statistically significantly associated with use of RRMed (OR 1.82, 95%CI: 1.08–3.07, p = 0.02 for ≥30% lifetime risk compared with 16%–29% lifetime risk), but parity, education level and family history of breast cancer were not. Breast cancer prevention medications are underutilised. Efforts are needed to incorporate breast cancer risk assessment and risk management discussions into routine health assessments for women.
topic Breast cancer
Prevention
Chemoprevention
Tamoxifen
Risk
url http://www.sciencedirect.com/science/article/pii/S0960977621004434
work_keys_str_mv AT courtneymacdonald underutilisationofbreastcancerpreventionmedicationinaustralia
AT jamesachamberlain underutilisationofbreastcancerpreventionmedicationinaustralia
AT daniellemazza underutilisationofbreastcancerpreventionmedicationinaustralia
AT rogerlmilne underutilisationofbreastcancerpreventionmedicationinaustralia
AT kellyannephillips underutilisationofbreastcancerpreventionmedicationinaustralia
_version_ 1721187813315051520

Similar Items